<DOC>
	<DOCNO>NCT00285025</DOCNO>
	<brief_summary>The primary objective demonstrate SR57667B dose 4 mg/day , comparison placebo , decrease decline cognitive performance global clinical decline 1 year patient mild moderate AD . Secondary objective assess effect SR57667B functional decline safety/tolerability patient mild moderate AD , document plasma concentration SR57667 patient mild moderate AD .</brief_summary>
	<brief_title>Study Effect SR57667B Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Multinational , multicenter , randomize , parallel-group , double-blind , phase II study</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male / female outpatient . Age &gt; 50 year screen . Dementia Alzheimer ’ Type ( DSMIV 290.0 ) accord DSMIV criterion , Probable AD accord NINCDSADRDA criterion , MiniMental State Examination score &gt; 12 &lt; 26 . Untreated treat minimum 6 month randomization stable dose cholinesterase inhibitor Generally healthy ambulatory ambulatoryaided ( i.e. , walker cane ) . Presence reliable caregiver . Patient , identify caregiver , applicable , patient surrogate ( primary relative , legal guardian , medical proxy ) give informed write consent capable follow study procedure Any cause dementia due Alzheimer ’ disease , Delusions , delirium , psychosis , depression , significant psychiatric disorder . Treatment register putative cognitive enhancer disease modifier donepezil , rivastigmine galantamine . Females pregnant breastfeeding . Females child bear potential ( premenopausal female biologically capable become pregnant ) must confirm negative serum b–HCG pregnancy test screen visit , must use acceptable method birth control . Severe unstable cardiovascular , respiratory , renal , hematological , endocrinological , neurological somatic disease . Use CYP3A4 strong inhibitor Evidence ( detected history , physical examination / laboratory / ECG test ) clinically significant unstable medical disorder could interfere subject 's participation clinical trial ; interfere absorption , metabolism excretion study medication ; interfere evaluation study drug . Alterations laboratory test ECG finding potential clinical significance .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>nerve growth factor</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>